XXXX inhibitors, superinfection and @entity288 affect survival of @entity683 @entity1 .

@entity1 @entity689 @entity11925 @entity684 @entity685 @entity55 @entity683 @entity1576 @entity23217 @entity204 @entity288
UNASSIGNED: We aimed to study factors influencing outcomes of adults hospitalised for seasonal and pandemic @entity683 .   Individual- @entity1 data from three Asian cohorts (Hong Kong, Singapore and Beijing; N=2649) were analysed. Adults hospitalised for laboratory-confirmed @entity683 (prospectively diagnosed) during 2008-2011 were studied. The primary outcome measure was 30-day survival. Multivariate Cox regression models (time-fixed and time-dependent) were used. @entity1 had high morbidity (respiratory/nonrespiratory complications in 68.4%, @entity1576 in 48.6%, @entity55 in 40.8% and bacterial superinfections in 10.8%) and mortality (5.9% at 30   days and 6.9% at 60   days). 75.2% received @entity689 inhibitors ( @entity11925 ) (73.8% received @entity684 and 1.4% received @entity23217 / @entity685 ; 44.5% of @entity1 received @entity11925    2   days and 65.5%    5   days after onset of illness); 23.1% received systemic @entity288 . There were fewer @entity204 among @entity11925 -treated @entity1 (5.3% versus 7.6%; p=0.032). @entity11925 treatment was independently associated with survival (adjusted hazard ratio (HR) 0.28, 95% CI 0.19-0.43), adjusted for treatment-propensity score and @entity1 characteristics. Superinfections increased (adjusted HR 2.18, 95% CI 1.52-3.11) and chronic statin use decreased (adjusted HR 0.44, 95% CI 0.23-0.84) death risks. Best survival was shown when treatment started within    2   days (adjusted HR 0.20, 95% CI 0.12-0.32), but there was benefit with treatment within 3-5   days (adjusted HR 0.35, 95% CI 0.21-0.58). Time-dependent analysis showed consistent results of @entity11925 treatment (adjusted HR 0.39, 95% CI 0.27-0.57). @entity288 increased superinfection (9.7% versus 2.7%) and @entity204 when controlled for indications (adjusted HR 1.73, 95% CI 1.14-2.62). Early @entity11925 treatment was associated with shorter length of stay in a subanalysis. @entity11925 treatment may improve survival of hospitalised @entity683 @entity1 ; benefit is greatest from, but not limited to, treatment started within 2   days of illness. Superinfections and @entity288 increase mortality. Antiviral and non-antiviral management strategies should be considered.
